Nemo and BEAT-Mesothelioma UK trials

The NEMO clinical trial, a multicentre, prospective, double blinded, randomised, two-arm phase II trial aiming to evaluate nintedanib as switch maintenance treatment, has been open for a while and is still looking to recruit patients.

Open centres in the UK are Wythenshawe Hospital, Manchester, Royal Marsden Hospitals, Chelsea, Sutton and Kingston, Weston Park Hospital, Sheffield, and South Tyneside District Hospital, South Shields.

The BEAT-Meso clinical trial is a new trial which opened in August at the Royal Marsden Hospitals (Chelsea and Sutton), and Truro Hospital. The team is looking for newly diagnosed mesothelioma patients to take part. The aim of this clinical trial is to assess the effect of treatment with an immunotherapy monoclonal antibody called atezolizumab in patients diagnosed with malignant pleural mesothelioma.

The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated.

Sites will also be set up at Maidstone, Sheffield, Guys, Addenbrookes, Plymouth, Clatterbridge and Wythenshawe. Patients should speak to their oncologist about a referral for clinical trials.